SIM
GNMX

Spark Investment Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Spark Investment Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-77,400
Closed -$465K – 885
2015
Q4 		$465K Buy
+77,400
New +$526K 0.06% 391
2015
Q2 		– Sell
-15,400
Closed -$124K – 782
2015
Q1 		$124K Buy
15,400
+4,100
+36% +$30.9K 0.02% 600
2014
Q4 		$57K Sell
11,300
-2,200
-16% -$10.9K 0.01% 633
2014
Q3 		$70K Buy
+13,500
New +$87.1K 0.01% 616

Other funds holding GNMX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Spark Investment Management's GNMX Position: Q1 2016 in Review

Spark Investment Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2016, closing a stake of 77,400 shares — an estimated $465K sold.

Spark Investment Management first reported a position in GNMX in Q3 2014 and held it in 4 quarters. The position peaked at $465K in Q4 2015. 56 funds tracked by Wall St. Rank hold GNMX as of Q1 2016.

  • Spark Investment Management reported no remaining Aevi Genomic Medicine Inc position as of Q1 2016 after selling out during the quarter.
  • Spark Investment Management sold 77,400 Aevi Genomic Medicine Inc shares in Q1 2016, an estimated $465K.
  • Spark Investment Management first reported a position in Aevi Genomic Medicine Inc in Q3 2014 and held it in 4 quarters.
  • Spark Investment Management's Aevi Genomic Medicine Inc position peaked at $465K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2016.

Based on Spark Investment Management's 13F filing for Q1 2016, filed 12 May 2016.